Table of Contents
Volume 5 | Supplement 1
Publication Date: December 2006- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Introduction | ||
S6 |
Renal Cell Carcinoma: Development of a New Treatment Paradigm Ronald M. Bukowski |
|
Contributions | ||
S7-S18 |
Pathways of Dysregulation in Renal Cell Carcinoma: Rational Approaches to Development of Novel Treatment Mohamad K. Khasawneh, Ronald M. Bukowski |
|
S19-S23 |
Tyrosine Kinase Inhibitors Compared with Cytokine Therapy for Metastatic Renal Cell Carcinoma: Overview of Recent Clinical Trials Differentiating Clinical Response and Adverse Effects Robert Dreicer |
|
S24-S30 |
Improving Outcomes with Novel Therapies for Patients with Newly Diagnosed Renal Cell Carcinoma JoEllen Speca, Sarah Yenser, Patricia Creel, Daniel George |
|
S31-S39 |
Targeting Growth Factor and Antiangiogenic Pathways in Clear-Cell Renal Cell Carcinoma: Rationale and Ongoing Trials Thomas E. Hutson, Guru Sonpavde, Matthew D. Galsky |
|
S40-S44 |
Therapeutic Considerations in Patients with Metastatic Renal Cell Carcinoma Previously Treated with Antiangiogenic Therapies Saby George, Brian I. Rini |
|